ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...
The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 1:00 PM ESTCompany ParticipantsJoshua Bleharski - ...
Delve into the Astellas playbook, a strategy relying on "strategic brand" and advancing on "primary focuses" at the same time ...
Rintatolimod (Ampligen) combined with durvalumab (Imfinzi) has continued to exhibit encouraging efficacy, safety, and ...
Explore Sun Pharma's strong portfolio, innovative launches, and investment potential amidst market volatility for long-term growth.
7d
U.S. FDA Approves Novocure's Optune Pax(R) for the Treatment of Locally Advanced Pancreatic Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...
Novocure announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult ...
Citius Oncology, Inc. ("Citius Oncology") , the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , today announced that it has entered into an exclusive distribution ...
Precise coordination of cell growth and cell-cycle progression is essential for maintaining tissue integrity and organismal health. When these regulatory ...
A new study has uncovered a hidden step that helps the deadliest malaria parasite survive and multiply inside the human body. Researchers studying Plasmodium falciparum found that the parasite relies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results